Oruka Therapeutics (ORKA) Free Cash Flow (2010 - 2026)
Oruka Therapeutics (ORKA) posted quarterly Free Cash Flow of -$23.7 million for Q1 2026, down 13.26% year-over-year from -$27.3 million in Q1 2025, and down 4.31% quarter-over-quarter from -$22.7 million in Q4 2025.
Oruka Therapeutics (ORKA) Free Cash Flow (2010 - 2026) Analysis & Trends
Oruka Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$23.7 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 13.26% year-over-year to -$23.7 million; the TTM figure through Mar 2026 stood at -$91.2 million (down 16.09% YoY), while the FY2025 annual figure was -$88.4 million, down 52.76% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$23.7 million, down from -$22.7 million in the prior quarter.
- The five-year high for Free Cash Flow was -$168000.0 in Q1 2024, with the low at -$27.8 million in Q3 2024.
- The 5-year median for Free Cash Flow is -$4.3 million (2022), against an average of -$10.9 million.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow soared 89.47% in 2024, then plunged 12329.76% in 2025.
- Oruka Therapeutics' Free Cash Flow stood at -$1.5 million in 2022, then gained by 29.22% to -$1.1 million in 2023, then sank by 1682.01% to -$18.8 million in 2024, then fell by 20.49% to -$22.7 million in 2025, then retreated by 4.31% to -$23.7 million in 2026.
- Business Quant data shows ORKA's Free Cash Flow at -$23.7 million in Q1 2026, -$22.7 million in Q4 2025, and -$21.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Oruka Therapeutics | 6.98 Bn | 5.25 Bn | - | -33.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -33.15 Mn |
| Jun 30, 2026 | -33.15 Mn |
| Mar 31, 2026 | -23.65 Mn |
| Mar 31, 2026 | -23.65 Mn |
| Dec 31, 2025 | -22.67 Mn |
| Dec 31, 2025 | -22.67 Mn |
| Sep 30, 2025 | -21.68 Mn |
| Sep 30, 2025 | -21.68 Mn |
| Jun 30, 2025 | -23.18 Mn |
| Jun 30, 2025 | -23.18 Mn |
| Mar 31, 2025 | -20.88 Mn |
| Mar 31, 2025 | -20.88 Mn |
| Dec 31, 2024 | -18.82 Mn |
| Dec 31, 2024 | -18.82 Mn |
| Sep 30, 2024 | -27.82 Mn |
| Sep 30, 2024 | -27.82 Mn |
| Jun 30, 2024 | -11.03 Mn |
| Jun 30, 2024 | -11.03 Mn |
| Mar 31, 2024 | -168,000.00 |
| Mar 31, 2024 | -168,000.00 |